Patents by Inventor Katherine Diana Cygnar

Katherine Diana Cygnar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11578135
    Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: February 14, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Aris N. Economides, Katherine Diana Cygnar
  • Publication number: 20210115132
    Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.
    Type: Application
    Filed: April 25, 2019
    Publication date: April 22, 2021
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Aris N. Economides, Katherine Diana Cygnar
  • Publication number: 20190309061
    Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.
    Type: Application
    Filed: April 25, 2019
    Publication date: October 10, 2019
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Aris N. Economides, Katherine Diana Cygnar
  • Publication number: 20130243775
    Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 19, 2013
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Nicholas J. PAPADOPOULOS, Andrew J. Murphy, Aris N. Economides, Katherine Diana Cygnar